LONDON, March 27 (Reuters) - Akzo Nobel NV (AKZO.AS: Quote, Profile, Research) hopes to reveal some Phase III clinical data on antipsychotic drug asenapine before the IPO of its pharma unit in the second half of this year, the Dutch group said on Monday.
